infliximab-dyyb (Zymfentra) vs SOR102
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
infliximab-dyyb (Zymfentra)
Marketed by Celltrion
NCT04205643 · Phase 3 · completed
The trial was randomized, quadruple-blind, and placebo-controlled, with 548 participants enrolled and 438 participants included in the reported maintenance analysis. The hard clinical primary endpoint—clinical remission by the modified Mayo score at week 54—was met, with 127 of 294 participants receiving CT-P13 versus 30 of 144 receiving placebo (p<0.0001).
No aligned efficacy figure on record for this race.
SOR102
Developed by Sorriso Pharmaceuticals
NCT06080048 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Treatment Emergent Adverse Events following oral dosing". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Reported efficacy
Treatment Emergent Adverse Events following oral dosing (Up to 6 weeks in Part 3 or at the time of study discontinuation): First-in-human phase 1. Part 1 (healthy participants): treatment-emergent adverse events in 3/24 (13%) receiving SOR102 versus 2/8 (25%) receiving placebo. Part 2: no treatment-emergent adverse events in the 10 participants receiving twice-daily SOR102. Part 3 (ulcerative colitis patients): at least one adverse event in 7/16 (44%) treated with SOR102 and 3/6 (50%) receiving placebo. Rates of clinical response ranged from 29% to 67%, depending on the definition applied.
Result source: NCT06080048
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | infliximab-dyyb (Zymfentra) | SOR102 |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Clinical response (induction) | —Not reported | —Not reported |
| Endoscopic improvement (induction) | —Not reported | —Not reported |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- infliximab-dyyb (Zymfentra)
- —Not reported
- SOR102
- —Not reported
Clinical remission (maintenance)
- infliximab-dyyb (Zymfentra)
- —Not reported
- SOR102
- —Not reported
Clinical response (induction)
- infliximab-dyyb (Zymfentra)
- —Not reported
- SOR102
- —Not reported
Endoscopic improvement (induction)
- infliximab-dyyb (Zymfentra)
- —Not reported
- SOR102
- —Not reported
Corticosteroid-free remission (maintenance)
- infliximab-dyyb (Zymfentra)
- —Not reported
- SOR102
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
infliximab-dyyb (Zymfentra): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.
SOR102: no structured comparison results are available for Ulcerative Colitis.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: infliximab-dyyb (Zymfentra)'s landscape · SOR102's landscape